Post-transcriptional tRNA modifications are numerous and require a large set of highly conserved enzymes in humans and other organisms. In yeast, the loss of many modifications is tolerated under unstressed conditions; one exception is the N 6 -threonylcarbamoyl-adenosine (t 6 A) modification, loss of which causes a severe growth phenotype. Here we aimed at a molecular diagnosis in a brother and sister from a consanguineous family who presented with global developmental delay, failure to thrive and a renal defect manifesting in proteinuria and hypomagnesemia. Using exome sequencing, the patients were found to be homozygous for the c.974G4A (p.(Arg325Gln)) variant of the KAE1 gene. KAE1 is a constituent of the KEOPS complex, a fivesubunit complex that catalyzes the second biosynthetic step of t 6 A in the cytosol. The yeast KAE1 allele carrying the equivalent mutation did not rescue the t 6 A deficiency of the kae1Δ yeast strain as efficiently as the WT allele; furthermore, t 6 A levels quantified by LC-MS/MS were lower in the kae1Δ strain which was complemented by the mutation than in the kae1Δ strain, which was complemented by the WT allele. We conclude that homozygosity for c.974G4A (p.(Arg325Gln)) in KAE1 likely exerts its pathogenic effect by perturbing t 6 A synthesis, thereby interfering with global protein production. This is the first report of t 6 A biosynthesis defect in human. KAE1 joins the growing list of cytoplasmic tRNA modification enzymes, all associated with severe neurological disorders. European Journal of Human Genetics (2017) 25, 545-551; doi:10.1038/ejhg.2017.30; published online 8 March 2017 INTRODUCTION Post-transcriptional modifications of RNA are ubiquitous, and among cellular RNAs, tRNA are by far the most extensively modified. A typical eukaryotic tRNA contains more than 10 modifications of different types and more than 120 distinct chemical modifications of tRNA nucleotide bases and sugars are known to date. 1,2 A correspondingly large number of enzymes have been identified that catalyze the numerous post-transcriptional tRNA modification reactions and these enzymes are often highly conserved, catalyzing similar modifications in multiple domains of life (reviewed in El Yacoubi et al. 3 ). In yeast, the absence of many tRNA modifications is tolerated under standard, unstressed growth conditions, though often resulting in error-prone translation. In only a few cases does the absence of tRNA modifications lead to severe growth phenotypes. One such example is the N 6 -threonyl-carbamoyl-adenosine (t 6 A) modification, a complex modification of adenosine located at position 37 (t 6 A37) next to the anticodon stem loop of many tRNAs that decode ANN codons. The absence of this modification is associated with a severe growth phenotype in yeast, 4,5 possibly due to the fact that t 6 A is a precursor
INTRODUCTION
Post-transcriptional modifications of RNA are ubiquitous, and among cellular RNAs, tRNA are by far the most extensively modified. A typical eukaryotic tRNA contains more than 10 modifications of different types and more than 120 distinct chemical modifications of tRNA nucleotide bases and sugars are known to date. 1,2 A correspondingly large number of enzymes have been identified that catalyze the numerous post-transcriptional tRNA modification reactions and these enzymes are often highly conserved, catalyzing similar modifications in multiple domains of life (reviewed in El Yacoubi et al. 3 ). In yeast, the absence of many tRNA modifications is tolerated under standard, unstressed growth conditions, though often resulting in error-prone translation. In only a few cases does the absence of tRNA modifications lead to severe growth phenotypes. One such example is the N 6 -threonyl-carbamoyl-adenosine (t 6 A) modification, a complex modification of adenosine located at position 37 (t 6 A37) next to the anticodon stem loop of many tRNAs that decode ANN codons. The absence of this modification is associated with a severe growth phenotype in yeast, 4, 5 possibly due to the fact that t 6 A is a precursor in the synthesis of other hypermodified derivatives such as cyclic-t 6 A (ct 6 A), N 6 -methyl-t 6 A (m 6 t 6 A) 6, 7 and 2-methylthio-t 6 A (ms 2 t 6 A) (reviewed in ref. 8) . In mammals, the absence of ms 2 t 6 A37 in tRNA-Lys in pancreatic beta cells results in the reduction of glucose-stimulated proinsulin synthesis, linking t 6 A derivatives to diabetes. 9, 10 We now report a biosynthetic defect of the t 6 A molecule in two patients suffering from global developmental delay, failure to thrive and a renal defect manifesting by proteinuria and hypomagnesemia.
SUBJECTS AND METHODS Patients
The subjects of this study were two siblings, a female, patient II-1, and a male, II-2, the children of an Arab Muslim first cousin parents ( Figure 1a) . Their clinical data are presented below as well as in Table 1 . Patient II-1 was born at term with a birth weight of 2600 g. Dysmorphic features were noted at birth, including upturned nose, antimongoloid slant, high-arched palate and thoracolumbar kyphosis. Her clinical course was characterized by failure to thrive due to impaired swallowing (at 4 years, her weight was 11 kg), acquired microcephaly, hypotonia and gross motor delay, with both comprehensive and expressive language skills being severely impaired. At 6 years, she was unable to sit unsupported and her vocabulary was confined to 5-10 words.
Brain MRI performed at the age of 4 years was reportedly normal except for cerebellar atrophy though the images were not available for review. The EEG was normal. Muscle biopsy disclosed type II atrophy.
Laboratory investigation revealed severe hypomagnesemia with normal calcium and albumin levels. A 24 h urine collection disclosed renal magnesium wasting combined with hypercalciuria and proteinuria. Normal serum magnesium levels were achieved with oral magnesium supplementation. The karyotype was 46XX and the metabolic screen was normal.
At 4 years, she was admitted with hypertensive crisis (blood pressure 120/180) that did not respond to intravenous hydralazine but normalized following intravenous β1-blocker (Esmolol) that was later replaced by oral propranolol and hydralazine. The cause of this event remained obscure as creatinine clearance, Doppler of renal arteries, blood levels of cortisol, ACTH, renin, aldosterone, PTH and thyroid parameters were all normal as was Synthesis defect of t 6 A modification of tRNA S Edvardson et al echocardiography. At the age of 6 years and 6 months, she was admitted with severe hypomagnesemia (0.1 mM, N = 0.7-1.1), tachycardia and tachypnea. She improved on intravenous magnesium, but on the third day developed hypertensive crisis, which was refractory to treatment and led to her death. Her brother, patient II-2 was born at term, with birth weight of 3800 g. Routine ultrasound examination during the pregnancy disclosed a hypoplastic left heart and aortic coarctation. At birth, physical examination revealed frontal bossing, bilateral microphthalmia, bilateral coloboma, bilateral ptosis, antimongoloid slant, strabismus, nystagmus, pectus excavatum and chest wall asymmetry, ichthyosis, arachnodactyly and cryptorchidism.
The patient underwent a cardiac surgical repair at 1 week of age and repair of pyloric stenosis at 4 months of age. Thereafter, the clinical course was characterized by failure to thrive, with microcephaly, nystagmus, hypotonia and gross motor delay, with both comprehensive and expressive language skills being severely impaired.
Brain MRI findings were consistent with leukodystrophy, showing increased T2 signal of white matter in a diffuse pattern (Figure 1d ). EEG was normal. A normal 46XY karyotype was also obtained. A metabolic screening panel was normal.
Blood tests revealed severe hypomagnesemia with hypocalcemia. A 24 h urine collection disclosed renal magnesium wasting combined with hypercalciuria, which were successfully treated with oral magnesium and calcium supplements. The patient died of respiratory insufficiency in association with pneumonia at 8 years of age.
Methods
Chemicals and reagents. Benzonase, deferoxamine, butylated hydroxytoluene, acetonitrile and buffer salts were purchased from Sigma-Aldrich (St Louis, MO, USA). Calf intestine alkaline phosphatase was obtained from Thermo Fisher (Waltham, MA, USA). Coformycin was obtained from the US National Cancer Institute. Phosphodiesterase I was purchased from US Biological (Salem, MA, USA). Tetrahydrouridine was purchased from Calbiochem (San Diego, CA, USA). Sartorius Vivaspin 500-brand centrifugal filter units were used for dialysis and sample concentration.
Whole exome sequencing and bioinformatic analysis. Exonic sequences were enriched in the DNA samples of patients II-1 and II-2 using SureSelect Human All Exon 50 Mb Kit V4 (Agilent Technologies, Santa Clara, CA, USA). Sequences were determined by HiSeq2000 (Illumina, San Diego, CA, USA) as 100-bp paired-end runs. Data analysis including read alignment and variant calling was performed by DNAnexus software (Palo Alto, CA, USA) using the default parameters with the human genome assembly hg19 (GRCh37) as reference. Parental consent was given for DNA studies. The study was performed with the approval of the ethical committees of Hadassah Medical Center and the Ministry of Health.
The gene variant database is available at www.LOVD.nl/OSGEP (patient ID #00095419).
For homology comparison: individual sequences were obtained from the National Center for Biotechnology Information (NCBI) database (http://www. ncbi.nlm.nih.gov/books/NBK44864/). Multiple alignments were generated using MultiAlin, 11 and the structures were visualized with the UCSF Chimera platform. 12 Growth media. Escherichia coli was grown in Luria Bertani (LB) medium (Fisher Scientific) at 37°C or on LB agar supplemented with ampicillin (Amp; 100 μg/ml); arabinose (Ara; 0.2%) or anhydrotetracycline (aTet; 250 ng/ml) were added as needed. The Escherichia coli Top10 strain (Invitrogen, Carlsbad, CA, USA) was routinely used for cloning.
Saccharomyces cerevisiae strains were routinely grown on YPD (DIFCO Laboratories) supplemented or not with G148 (0.2 mg/ml) at 30°C unless otherwise stated. Synthetic minimal, with or without Agar, SD base or SD base Gal/Raf without dropout (− uracil) were purchased from Clontech (Palo Alto, CA, USA) and prepared as recommended by the manufacturer.
Complementing the E. coli tsaD and tsaC essentiality phenotypes by co-expressing the human Tcs1/Tcs4 genes. Homo sapiens Tcs1 and Tcs4 cDNA sequences were obtained from the NCBI database. An E. coli codon-optimized synthetic gene operon of Tcs1-Tcs4 (sequence given in Supplementary Data) was purchased from Genscript and cloned in a pBAD24 plasmid 13 cut with NcoI/ SphI d. The resulting plasmid (pBAD24-Tcs1/4 Hs ) or the empty pBAD24 vector were used to transform E. coli strains VDC5684 (BW25113 P TET :tsaC) and VDC5801 (BW25113 P TET :tsaD). 14 Transformants were selected on LB agar supplemented with Amp and aTet.
Construction of pKae1 R376Q and complementation assays. Base changes leading to the R376Q mutation were introduced in the yeast KAE1/TCS2 gene cloned in the pYES derivative pKae1 4 by site-directed mutagenesis using the Q5 site-directed mutagenesis kit (New England Biolabs, NJ, USA) with the primers Fwd kae1 R376Q 5′-gcagaaattccaaaccgatgaag-3′ and RV kae1 5′-gtaacaacagtttcagaaaagtcct-3′ to give plasmid pKAE1_R376Q. The sequence of the insert was verified by Sanger DNA Sequencing (Eton Bioscience, San Diego, CA, USA).
For KAE1 complementation assays, the S. cerevisiae BY4741 kae1Δ strain (VDC5653) 4 was transformed with 1 μg of plasmid pKAE1 or pKAE1_R376Q as described in the Zymo Research handbook (Zymo Research, Irvine, CA, USA), then recovered with 2 ml of YPD and placed at 30°C for 2 h with shaking. Then the cells were pelleted by centrifugation, washed with 2 ml of water and resuspended in 100 μl of water before plating onto SD − uracil supplemented with G148 (0.2 mg/ml).
Isolated colonies of transformed cells were inoculated in 15 ml of SD − uracil supplemented with G148 (0.2 mg/ml) then diluted to an OD 600 = 0.009 in 1 l of SD base Gal/Raf without uracil, G148 (0.2 mg/ml) and grown at 30°C with shaking until they reach OD 600 = 0.5. The experiment was performed with two biological replicates.
Extraction of bulk tRNA. Bulk tRNA were prepared as previously described. 5 Briefly, tRNAs were extracted using acid-buffered phenol (saturated with 50 mM sodium acetate, pH 5.5) followed by ethanol precipitation. tRNA quality was evaluated by both 12% acrylamide, 8.0 M urea denaturing gel electrophoresis with ethidium bromide visualization and Bioanalyzer (Agilent Technologies) using a small RNA chip.
Positive hybridization in absence of t 6 A (PHAt 6 A) assay. Three volumes of denaturing solution (500 μl formamide, 162 μl 37% formaldehyde, 100 μl RNase-free 10X MOPS solution) was added to 1 μl of 1 ng/μl tRNA followed by tRNA denaturation at 85°C for 15 min. The mixture was cooled on ice and the final volume adjusted to 30 μl with 20X SSC (1.5 M sodium chloride, 0.15 M sodium citrate). The mixture was spotted on Biodyne A membrane (Thermo Prehybridization was performed by incubation in DIG Easy Hyb (Roche, Basel, Switzerland) for 60 min at 42°C with constant rocking. Biotinylated DNA probes were designed to complement the tRNA Ile IAU anticodon stem loop (5ʹ(biosg)-CCCCGCGTTATTAGCAC-3ʹ) and TΨC loop (5ʹ(biosg)-GCGGGATCGAACCGC-3ʹ). DNA probes (1 μl per 5 cm 2 of membrane) were denatured in DIG Easy Hyb at 95°C for 10 min before incubation with the membrane overnight at 40°C with constant rocking. Membranes were washed three times with 10X SSC for 10 min at ambient temperature. The membrane hybridized with the anticodon stem loop (ASL) probe was subjected to two extra washes, one at ambient temperature and another at 42°C. Detection and visualization was performed with North2South Chemiluminescent Detection Kit, as described by the manufacturer (Thermo Scientific).
Mass spectrometric analysis of t 6 A level. Two micrograms of bulk tRNA from each sample were hydrolyzed to ribonucleosides in a reaction containing Benzonase (0.375 U), calf intestine alkaline phosphatase (8.5 U), phosphodiesterase I (0.05 U), coformycin (3.5 μM; nucleobase deaminase inhibitor), deferoxamine (3 mM; antioxidant), butylated hydroxytoluene (0.3 mM; antioxidant) and MgCl 2 (5 mM) in a final reaction volume of 50 μl. The reaction was allowed to proceed for 2 h at 37°C and was stopped by removal of the enzymes by microfiltration with 10 000 Da spin filters. Following the addition of [ 15 N 5 ]-2'-deoxyadenosine as an internal standard for data normalization, ribonucleosides were resolved on a Synergy Fusion RP HPLC column (2.5 μm particle size, 100 Å pore size, 100 mm length, 2 mm inner diameter; Phenomenex, Torrance, CA, USA) mounted on an Agilent 1290 series HPLC system equipped with a diode array detector (DAD). The ribonucleosides were eluted at a flow rate of 0.35 ml/min and a column temperature of 35°C with a gradient consisting of 5 mM ammonium acetate (A) and acetonitrile (B) as follows: 0-1 min 100% A, 1-10 min 0-10% B, 10-24 min 10-40% B, 24-44 min 40-80% B, and 44-49 min 100% A to regenerate the column. The column, with its eluent directed through the DAD to record the 260 nM absorbance of canonical ribonucleosides, was coupled to an Agilent 6430 triple quadrupole mass spectrometer operated in positive ion mode with the following parameters: electro-spray ionization (ESI-MS), fragmentor voltage (average) 80 V, cell accelerator voltage 2 V, N 2 -gas temperature 350°C, N 2 -gas flow 10 l/min, nebulizer 40 p.s.i., capillary 3500 V. Using dynamic multiple reaction monitoring (MRM), modified ribonucleosides were identified based on retention time (t 6 A at 7.9-8.3 min) and mass transition (m/z 413 →281 for loss of ribose from t 6 A). The signal for t 6 A was normalized by dividing by the peak area of the [ 15 N 5 ]-dA standard (inter-sample variation) and by the summed MRM peak areas of the canonical ribonucleosides (input RNA variation). The normalized peak areas of two biological replicates were then averaged.
RESULTS
Exome analysis of patients II-1 and II-2 yielded 57.0 and 71.3 million mapped reads with a mean coverage of X83 and X111, respectively. Following alignment to the reference genome (Hg19) and variant calling, we performed coverage analysis, which was normal in patient II-1 but disclosed a duplication of hg19 Chr1: g.146638410_ 147380068dup in patient II-2 sample. The duplication included the genes PRKAB2, FMO5, CHD1L, BCL9, ACP6 and GJA5. Gains at 1q21.1, which span these genes, were previously reported to be significantly enriched among patients with congenital heart defects including tetralogy of Fallot, coarctation of the aorta and Shone's syndrome. These malformations were present even when the duplicated region was only 0.4 Mb long and included only PRKAB2, FMO5 and CHD1L. 15, 16 We propose that the hypoplastic left heart and aortic coarctation, microphthalmia, bilateral coloboma, ichthyosis and arachnodactyly are all resulting from the Chr1q21.1 duplication.
Using the patients' variant lists, we performed a series of filtering steps under the hypothesis of a recessively inherited, homozygous, rare, causal allele. These included removing variants that were not shared by both patients, called less than X8, were off-target, heterozygous, synonymous, on the X chromosome, had MAF 41% at ExAC (Exome Aggregation Consortium, Cambridge, MA; URL: http://exac. broadinstitute.org) or MAF 44% at the Hadassah in-house database. Eleven homozygous variants remained (Supplementary Table S1 ), but, after genotyping the healthy sister and removing rare variants that were present in ExAC in homozygosity, we focused on hg19 chr14: g.20915433C4T, NM_017807.3:c.974G4A, p.(Arg325Gln; R325Q) in KAE1 (OSGEP). This variant affected an evolutionary conserved residue (Figure 1b) , segregated in the family (Figure 1c) , was carried by only 2 of the 60 700 individuals whose exome analyses were deposited at ExAC (accessed July 2016), and was not present in our inhouse database (~900 Moslem-Arab exome analyses).
KAE1 encodes the TCS3/OSGEP/Kae1 protein that is a constituent of the KEOPS (Kinase, Endopeptidase and Other Proteins of small Size) complex. KEOPS complex participates in the synthesis of t 6 A, a modification commonly occurring in many tRNAs at position A37 (see Thiaville et al., 17 for review). A reconstruction of t 6 A synthesis in H. sapiens based on similarity with experimentally validated enzymes is shown Figure 2 . t 6 A biosynthesis starts with the generation of threonylcarbamoyladenylate (TC-AMP ) from ATP, threonine and C0 2 , which is catalyzed by Tcs1/YrdC or Tcs2/Sua5. [18] [19] [20] The KEOPS complex catalyzes the second biosynthetic step in the cytosol, the transfer of the carboxythreonyl moiety from the TC-AMP intermediate to the adenosine on the target tRNA, with KAE1 catalyzing this activity in humans.
To examine the highly conserved Arg325 residue in the context of the entire KAE1 protein, we used the crystal structure of Methanocaldococcus jannaschii (Mj) Tcs3/Kae1 in complex with Tcs5/Bud32. 21 Figure 2 Predicted synthesis pathway for the t 6 A modification and its derivatives in H. sapiens. This pathway was predicted from sequence similarity and has been experimentally validated by E. coli complementation (red; see also Supplementary Figure S2) , in vitro experiments (purple) or in vivo experiments in human cells (green). Ref_seq identifiers and synonyms are listed here: Tcs1/YrdC = NP_078916.3; Tcs3/Kae1/ OSGEP = NP_060277.1; Tcs4/Qri7/OSGEPL1 = NP_071748.2; Tcs5/Bud32/ PRPK = NP_291028.3; Tcs6/Cgi121/TPRKB = NP_057142.1; Tcs7/Pcc1/ LAGE3 = NP_006005.2; Tcs8/Gon7/C14orf142 = NP_115879.2; TrmO = NP_057565.3; CDKAL1/MtaB = NP_060244.2. The full colour version of this figure is available at European Journal of Human Genetics online.
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In this structure (PDB: 3ENH), the conserved Arg (R315) is located at the periphery of the major binding interface between Tcs3/Kae1 and Tcs5/Bud32 (highlighted in red); the R315 side chain is displayed in the M. jannaschii protein structure in Supplementary Figure S1 . The residue does not appear to participate in binding with Tcs5/Bud32, though mutations of residues in its proximity have been shown to present moderate growth defects. 21 The Mj Kae1-Bud32 complex is exceptional because the two genes kae1 and bud32 are fused together and code for a single polypeptide. Consequently, the interaction surface (and the position of R315) between the two domains may be significantly different compared with human orthologs. Further, R315 is found in a signature motif that separates the Tcs3/Kae1 subfamily from the other members of the ASKHA ATPase family. 21 Interestingly, this region shows some dynamics in folding depending on the context, as observed when comparing the structures of Kae1/Bud32 fusion alone (PDB: 3EN9) to those in complex with Bud32/Cgi121 (PDB: 3ENH). We observed that R315 is contained in a loop in PDB:3ENH while the residue is in a helical structure in PDB:3EN9. Further biochemical and structural studies are required to fully understand the functional importance of this strongly conserved residue.
To demonstrate that the KAE1 R325Q variant affects t 6 A synthesis, we took advantage of the strong homology between human and yeast KAE1 protein (Figure 1b ). We and others have previously shown that tRNAs extracted from kae1Δ yeast strains are devoid of t 6 A and that this phenotype is partially complemented by expressing the WT KAE1 gene in trans on a plasmid (pKAE1). The position equivalent to R325 in the S. cerevisiae enzyme is R376 (Figure 1b) . A pKae1 derivative harboring the R376Q mutation (pKAE1_R376Q) was constructed as described in the 'Methods' section and tested for complementation of the t 6 A deficiency phenotype of the S. cerevisiae kae1Δ strain. A t 6 A hybridization assay that produces a signal only in the absence of t 6 A 22 was first used. Under specific stringency conditions, an oligonucleotide targeted to the anticodon stem loop (ASL) region of tRNA Ile IAU binds only when the t 6 A modification is absent, such as in the kae1Δ strain (Figure 3a, left panel) . This binding was totally eliminated when the WT KAE1 gene was expressed in trans but only partially eliminated when the mutant allele (KAE1_R376Q) was expressed (Figure 3a , right panel). These findings suggested that pKAE1_R376Q is unable to fully rescue the t 6 A synthesis defect of kae1Δ yeast strain. To further validate this result, t 6 A levels were quantified by liquid chromatographycoupled tandem mass spectrometry (LC-MS/MS). As shown in Figure 3b , tRNA extracted from the kae1Δ mutant transformed with the pKAE1_R376Q plasmid contained approximately 25% less t 6 A than the one transformed with the WT control. As a control for the fold-change analysis, the abundance ratios of the canonical ribonucleosides remained close to 1 as expected. Normalized levels of t 6 A in both sets of complementation samples were similar (well within one standard deviation of the mean for the two biological replicates). Of note, the pKAE1_R376Q plasmid was found to regularly revert to the WT sequence in the course of the experiment, so the reduction in t 6 A synthesis reported here might be an underestimate.
DISCUSSION
The identification of disease-associated genes in patients with primary neuronal degenerative disorders was recently accelerated, thanks to the introduction of exome analysis. The major challenge for this platform is rare variant filtering, which is markedly alleviated when the patient is the product of a consanguineous marriage, as only homozygous variants are retained. Consanguinity is practiced by approximately 20% of the human population and amounts to 31% among Israeli Arabs 23 and 40% among Palestinian Arabs. 24 Since 2011, we have recognized as a cause of human diseases, most commonly involving the brain, as in PUS3, ADAT3, WDR4, NSUN2 and FTSJ1 mutations. [40] [41] [42] [43] [44] Additional organ systems are less frequently affected in cytosolic tRNA modification defects, such as pancreatic beta cells in TRMT10A mutations 45 and, in the present report, a KAE1 mutation that affects renal tubuli.
In summary, homozygosity for R325Q in the KAE1 gene is associated with global developmental delay, failure to thrive, and a renal tubular defect. The mutation appears to exert its pathogenic effects by perturbing t 6 A synthesis, possibly interfering with global protein synthesis. KAE1 is the first reported t 6 A biosynthesis defect in humans and joins the growing list of cytoplasmic tRNA modification enzymes associated with severe neurological disorders. Figure 3 Ribonucleoside quantification in tRNA extracted from S. cerevisiae Δkae1 transformed with plasmids expressing the wild-type (WT) yeast KAE1 gene (pKAE1) or the derivative carrying the R376Q mutation (pKAE1 R376Q). (a) Northern dot-blot assay for the detection of t 6 A in bulk tRNA preparations. Hybridization with a probe against the tRNA Ile IAU ASL shows a signal only when t 6 A is absent. The probe specific to the TΨC loop is used to measure the quantity of tRNA. Lanes with sua5Δ (catalyzes threonylcarbamoyladenylate synthesis) and kae1Δ serve as controls to demonstrate the lack of t 6 A synthesis. (b) LC-MS/MS analysis of t 6 A in bulk tRNA preparations. The fold-change values for complementation of the mutant compared with the WT alleles were calculated and averaged. The data represent mean ± error about the mean for two biological replicates.
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